Florida Cancer Specialists & Research Institute Contributes to Shaping Future Cancer Care Policy & Innovations At Patient-Centered Oncology Care® Conference

FORT MYERS, Fla., Sept. 24, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians, clinicians and leaders will contribute real-world insights and perspectives on the opportunities and challenges shaping modern oncology at the Patient-Centered Oncology Care® (PCOC) conference presented by The American Journal of Managed Care® (AJMC).

Lucio N. Gordan, MD, FCS president & managing physician, will present key insights from the 2026 J&J Oncology Care Index, an annual research initiative that provides a comprehensive snapshot of the evolving oncology landscape from the provider perspective, particularly in the community oncology setting where most patients receive treatment.

"The recent findings highlight several important realities in oncology — from keeping pace with rapidly evolving treatments and guidelines and translating emerging therapies into real-world practice to harnessing the promise of artificial intelligence and addressing barriers to expand access to cutting-edge clinical trials," Dr. Gordan said. "Our patients trust us to deliver the best care possible, and I look forward to sharing these findings as we continue working toward meaningful solutions that benefit patients and providers alike."

FCS Assistant Managing Physician David Wenk, MD said, "The pace of change in cancer care is extraordinary and underscores the importance of collaboration. As the leading provider of community-based cancer care across Florida for more than 40 years, FCS is proud to join fellow oncology leaders in examining the trends, innovations and care delivery strategies that are redefining cancer care and patient outcomes."

The following individuals from FCS will also participate in panel discussions that examine how coverage decisions, clinical guidelines and formulary strategies influence patient access to care, while highlighting innovative approaches to care delivery, practice optimization and patient support:

• Josh Eaves, FCS chief development & strategy officer - Scaling the Oncology Practice for Tomorrow's Patients
• Kiana Mehring, MBA, PPMC, FCS senior vice president, payer strategy, revenue cycle operations and value-based care - A Payer's Perspective on NCCN Guideline–Concordant Care
• Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, FCS senior director, pharmacy operations - Owning the Outpatients: The Role of Oncology Pharmacy in Bringing Novel Therapies to Earlier Lines of Care
• Jeanine Ksar, PharmD, BCOP, FCS clinical oncology pharmacist - From FDA to Formulary: A Look at Therapy Selection in Comprehensive Cancer Centers

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home. Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute